- Sequenom (SQNM +3.6%) subsidiary Sequenom Laboratories plans to launch its VisibiliT laboratory-developed test (LDT) next month in ex. U.S. markets. The test utilizes chromosomal material from chromosomes 18 and 21 in combination with maternal age and fetal fraction to generate a personalized risk score for fetal trisomies such as Down syndrome and Edwards syndrome. The test is performed using a maternal blood sample and applies to a single gestation pregnancy considered to be at average risk.
- The company intends to offer the test in the U.S. after insurance coverage is established.
Sequenom to launch new prenatal test next month
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Thu, 8:25AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs